Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.
Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.
One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.
The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.
Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.
For more information, visit Tonix Pharmaceuticals Holding Corp.
Rhea-AI Summary
Tonix Pharmaceuticals (TNXP) has developed a bedtime drug targeting fibromyalgia's poor sleep quality, showing promising results in reducing widespread pain. The drug, Tonmya, demonstrated significant pain improvement in a phase 3 study, with a potential FDA approval in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces CEO's participation at BIO CEO & Investor Conference to discuss the company's pipeline of development candidates, including positive Phase 3 studies for fibromyalgia treatment and plans for NDA submissions. The company's focus on CNS disorders and rare diseases, breakthrough therapy designation for TNX-1300, and vaccine development for smallpox and COVID-19 are highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) reported positive Phase 3 trial results for its non-opioid painkiller for fibromyalgia, achieving the primary endpoint with a p-value of 0.00005. The drug, Tonmya, showed promising results in reducing pain, improving sleep, and reducing fatigue. With potential FDA approval in 2025, Tonmya could offer a new treatment option for fibromyalgia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive Phase 3 data for Tonmya™ (TNX-102 SL) for fibromyalgia management, showcasing significant reduction in pain, fatigue, and sleep disturbance. Plans to file for FDA approval in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. engages Rho, Inc. for NDA submission of Tonmya™, a potential first-line therapy for fibromyalgia. Positive Phase 3 results show significant pain reduction compared to placebo, with plans for NDA submission in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces FDA clearance for Phase 2 OASIS trial to evaluate TNX-102 SL in reducing acute stress reaction severity and frequency of stress disorders. The trial is sponsored by UNC and supported by DoD grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.12%
Tags
Rhea-AI Summary
Tonix Pharmaceuticals (NASDAQ:TNXP) has a potential new treatment for fibromyalgia with TNX-102 SL, hitting the primary endpoint of daily pain reduction with a p-value of 0.00005. TNX-102 SL targets poor sleep quality rather than sleep quantity, improving the daily lives of fibromyalgia patients. The company plans to file an NDA for FDA approval in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces the publication of a research paper in the Journal Pain, revealing that patients with pre-existing chronic overlapping pain conditions (COPCs) had an increased risk of being diagnosed with symptoms of Long COVID. The study found that COPCs and Long COVID likely result from the same or similar brain processes, and Long COVID can be conceptualized as a new onset COPC or an exacerbation of a pre-existing COPC. The company is studying TNX-102 SL for the management of fibromyalgia and management of fibromyalgia-type Long COVID. Tonix has plans to submit an NDA to the U.S. Food and Drug Administration in the second half of 2024 under the 505(b)(2) regulatory pathway for Tonmya for the management of fibromyalgia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced positive results from two Phase 3 studies for Tonmya (TNX-102 SL) in managing fibromyalgia, with plans to submit a New Drug Application to the FDA in the second half of 2024. The studies showed statistically significant reduction in daily pain and improvement in sleep quality, fatigue, and overall fibromyalgia symptoms. The FDA conditionally accepted the trade name Tonmya for TNX-102 SL, marking a significant step forward for the company in offering the first FDA-approved drug for fibromyalgia patients in more than a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of TNX-102 SL for the management of fibromyalgia. The webinar will feature two esteemed thought leaders in the field of fibromyalgia and will be hosted by Alliance Global Partners. The webinar will take place on January 31, 2024, at 1:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
FAQ
What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?
The current stock price of Tonix Pharmaceuticals Holding (TNXP) is $0.3275 as of January 23, 2025.
What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?
The market cap of Tonix Pharmaceuticals Holding (TNXP) is approximately 64.9M.
What is the main focus of Tonix Pharmaceuticals Holding Corp.?
Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.
What is Tonmya?
Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.
What are TNX-601 and TNX-801?
TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.
What is TNX-1500?
TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.
Which institutions is Tonix Pharmaceuticals affiliated with?
Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.
How can I get more information about Tonix Pharmaceuticals?
More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.
What areas of disease does Tonix Pharmaceuticals focus on?
Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.
What stage are TNX-601 and TNX-801 in?
Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.
Who can I contact for investor relations at Tonix Pharmaceuticals?
For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.
Who can I contact for media inquiries at Tonix Pharmaceuticals?
For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.
Tonix Pharmaceuticals Holding Corp.
Nasdaq:TNXP
TNXP Rankings
TNXP Stock Data
64.85M
186.60M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
United States of America
CHATHAM